Korro Bio, an RNA editing company focused on the discovery and development of novel genetic medicines, entered into an agreement with Genevant Sciences, a nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, to combine Korro’s RNA editing platform with Genevant’s LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD).

Terms of the agreement were not disclosed.

“At Korro, we are developing a novel class of genetic medicines by combining our editing technology with fit-for-purpose delivery modalities. For patients with Alpha-1 Antitrypsin Deficiency, a genetic disease with high unmet medical need, we endeavor to provide a therapeutic option that returns the level of circulating protein to within the normal range,” said Ram Aiyar, CEO and President of Korro Bio.

Alyar added: “Genevant’s expertise in the development of LNPs for clinical applications, coupled with our titratable and transient RNA editing therapies to address both liver and lung manifestations, position us well to deliver a best-in-class therapeutic for patients with AATD.”

Pete Lutwyche, President and CEO Genevant Sciences said: “The challenge of delivering RNA payloads safely and effectively to specific tissues has historically been a major obstacle to unlocking the broad therapeutic potential of RNA-based medicines. As leaders in the field, the key role that innovative LNP technology can play in overcoming this challenge has been a longtime focus of Genevant scientists. We are delighted to collaborate with Korro to pursue a much-needed new treatment option for AATD patients.”